Citizens Downgrades enGene Therapeutics to Market Perform

Benzinga Newsdesk www.benzinga.com Negative 94.5%

Neg 94.5% Neu 0% Pos 0%

Citizens analyst Silvan Turkcan downgrades enGene Therapeutics (NASDAQ:ENGN) from Market Outperform to Market Perform.

Comments

No comments yet. Be the first!